{"id":886236,"date":"2025-09-15T11:23:58","date_gmt":"2025-09-15T15:23:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/"},"modified":"2025-09-15T11:23:58","modified_gmt":"2025-09-15T15:23:58","slug":"important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/","title":{"rendered":"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf"},"content":{"rendered":"
\n

PHILADELPHIA, Sept. 15, 2025 (GLOBE NEWSWIRE) — <\/p>\n

\n
\n Applied Therapeutics <\/u>
\n <\/strong>
\n
\n (NASDAQ: APLT) \u2013 Class Action Reaches Settlement:<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Applied Therapeutics. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n A securities fraud class action against Applied Therapeutics, Inc. <\/strong>
\n (NASDAQ: APLT) and certain of its officers has reached a settlement.<\/strong>\u00a0\u00a0<\/p>\n

\n If you purchased <\/strong>
\n Applied Therapeutics <\/strong>
\n (NASDAQ: APLT) shares prior to <\/strong>
\n January 3, 2024,<\/strong>
\n and still hold shares today, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/applied-therapeutics-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085 to learn more. <\/strong>\n <\/p>\n

\n WHY?<\/strong> As alleged in a recently filed securities fraud class action complaint, Applied Therapeutics, Inc. (NASDAQ: APLT), through certain of its officers, provided positive statements to investors while, at the same time, disseminating false and materially misleading statements and\/or concealing material adverse facts concerning the true state of Applied Therapeutics\u2019 Phase III INSPIRE trial; notably, electronic data capture issues and a dosing error in the dose-escalation phase of the study. The Complaint further alleges that such statements absent these material facts caused Plaintiff and other shareholders to purchase Applied Therapeutics\u2019 securities at artificially inflated prices.<\/p>\n

On August 25, 2025, the parties reported to the Court that they had agreed to settle the securities fraud class action.<\/strong><\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased <\/strong>
\n Applied Therapeutics <\/strong>
\n (NASDAQ: APLT) shares prior to <\/strong>
\n January 3, 2024,<\/strong>
\n and still hold shares today, <\/strong>
\n please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/applied-therapeutics-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. <\/strong>$APLT #AppliedTherapeutics<\/p>\n

\n
\n DoubleVerify Holdings, Inc. (NYSE: DV):<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating whether certain officers and directors of DoubleVerify Holdings, Inc. (NYSE: DV) breached their fiduciary duties owed to the company.<\/p>\n

\n If you have held DoubleVerify Holdings, Inc. (NYSE: DV) shares since prior to November 10, 2023, and would like to learn more about the investigation and your rights, please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/doubleverify-shareholder-investigation\/<\/strong>
\n <\/a>
\n , <\/strong>
\n contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , or call us at 267-507-6085. You <\/strong>
\n can <\/strong>
\n seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong><\/p>\n

Why?<\/strong> As alleged in an underlying securities fraud class action complaint, DoubleVerify (NYSE: DV), via certain of its officers, failed to disclose that: (a) DoubleVerify\u2019s customers were shifting their ad spending from open exchanges to closed platforms, where the Company\u2019s technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (b) DoubleVerify\u2019s ability to monetize on Activation Services, the Company\u2019s high-margin advertising optimization services segment, was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (c) DoubleVerify\u2019s Activation Services in connection with certain closed platforms would take several years to monetize; (d) DoubleVerify\u2019s competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify\u2019s ability to compete effectively and adversely impacted the Company\u2019s profits; (e) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; (f) DoubleVerify\u2019s risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and (g) as a result of the above, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially false and\/or misleading or lacked a reasonable basis.<\/p>\n

\n What You Can Do Now:<\/strong>
\n Current DoubleVerify (NYSE: DV) shareholders who have held DoubleVerify shares since prior to November 10, 2023,<\/strong>
\n can <\/strong>
\n seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.<\/strong>\u00a0\u00a0 If you would like to learn more about this matter, you are encouraged to visit <\/strong>https:\/\/grabarlaw.com\/the-latest\/doubleverify-shareholder-investigation\/<\/strong><\/a>, contact Joshua H. Grabar at <\/strong>jgrabar@grabarlaw.com<\/strong><\/a>, or call 267-507-6085.<\/strong> $DV #DoubleVerify<\/p>\n

\n
\n Ibotta, Inc. (NYSE: IBTA):<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Ibotta, Inc. (NYSE: IBTA). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased Ibotta, Inc. shares on or shortly after the company\u2019s April 18<\/strong>
\n , 2024 IPO,<\/strong>
\n and still hold shares today, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/ibotta-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085, to learn more.<\/strong><\/p>\n

WHY?<\/strong> A federal securities fraud class action complaint alleges that statements made in Ibotta Inc\u2019s (NYSE: IBTA) Registration Statement issued in connection with Ibotta\u2019s April 18, 2024 initial public offering were false and\/or misleading when made because they did not properly warn investors of the risks concerning Ibotta\u2019s contract with The Kroger Co. Kroger\u2019s contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta\u2019s contract with Walmart, there was not a single warning of the at-will nature of Kroger\u2019s contract.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased Ibotta, Inc. (NYSE: IBTA) shares on or shortly after the company\u2019s April 18<\/strong>
\n , 2024 IPO,<\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/ibotta-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0 #Ibotta $IBTA<\/p>\n

\n
\n Treace Medical Concepts, Inc. (NASDAQ: TMCI)<\/u>
\n <\/strong>\n <\/p>\n

\n If you have held Treace Medical Concepts (NASDAQ: TMCI) shares continuously since prior to <\/strong>
\n May 8, 2023, you can<\/strong>
\n seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you<\/strong>. Visit <\/strong>https:\/\/grabarlaw.com\/the-latest\/treace-shareholder-investigation\/<\/a>, or <\/strong>contact Joshua H. Grabar at\u00a0<\/strong>jgrabar@grabarlaw.com<\/a>or call 267-507-6085 <\/strong>to learn more.<\/strong><\/p>\n

Why?<\/strong> A recently filed securities class action complaint alleges that, Treace Medical Concepts, Inc. (NASDAQ: TMCI), via certain of its officers, made materially false and\/or misleading statements and failed to disclose adverse facts about the Company\u2019s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, Treace Medical\u2019s revenue declined, and the Company needed to accelerate its plans to offer a product that served as an alternative to osteotomy (a surgical procedure involving the cutting and realignment of a bone to improve its position or function); and (3) Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n

\n What You Can Do Now: <\/strong>
\n Current Treace shareholders who have held Treace shares since prior to May 8, 2023,<\/strong>
\n can <\/strong>
\n seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. <\/strong>
\n If you would like to learn more about this matter, you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/treace-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact us at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , or call 267-507-6085.<\/strong> #Treace $TMCI<\/p>\n

\n Attorney Advertising Disclaimer<\/a>\n <\/p>\n

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: \u00a0267-507-6085
Email: jgrabar@grabarlaw.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, Sept. 15, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics (NASDAQ: APLT) \u2013 Class Action Reaches Settlement: Grabar Law Office is investigating claims on behalf of shareholders of Applied Therapeutics. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. A securities fraud class action against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its officers has reached a settlement.\u00a0\u00a0 If you purchased Applied Therapeutics (NASDAQ: APLT) shares prior to January 3, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/applied-therapeutics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or … <\/p>\n

Continue reading “Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-886236","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImportant Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Sept. 15, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics (NASDAQ: APLT) \u2013 Class Action Reaches Settlement: Grabar Law Office is investigating claims on behalf of shareholders of Applied Therapeutics. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. A securities fraud class action against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its officers has reached a settlement.\u00a0\u00a0 If you purchased Applied Therapeutics (NASDAQ: APLT) shares prior to January 3, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/applied-therapeutics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or … Continue reading "Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T15:23:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf\",\"datePublished\":\"2025-09-15T15:23:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/\"},\"wordCount\":1318,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/\",\"name\":\"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=\",\"datePublished\":\"2025-09-15T15:23:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/","og_locale":"en_US","og_type":"article","og_title":"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf - Market Newsdesk","og_description":"PHILADELPHIA, Sept. 15, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics (NASDAQ: APLT) \u2013 Class Action Reaches Settlement: Grabar Law Office is investigating claims on behalf of shareholders of Applied Therapeutics. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. A securities fraud class action against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its officers has reached a settlement.\u00a0\u00a0 If you purchased Applied Therapeutics (NASDAQ: APLT) shares prior to January 3, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/applied-therapeutics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or … Continue reading \"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-15T15:23:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf","datePublished":"2025-09-15T15:23:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/"},"wordCount":1318,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/","name":"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=","datePublished":"2025-09-15T15:23:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyOTAwMSM3MTQ2Nzc2IzIyMDEyNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-applied-therapeutics-inc-nasdaq-aplt-doubleverify-holdings-inc-nyse-dv-ibotta-inc-nyse-ibta-and-treace-medical-concepts-inc-nasdaq-tm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); DoubleVerify Holdings, Inc. (NYSE: DV); Ibotta Inc. (NYSE: IBTA); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=886236"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/886236\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=886236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=886236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=886236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}